Free shipping on all orders over $ 500


Cat. No. M25447
PR-104 Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy.

PR-104 (80 μM; 1 hour; SiHa cells) shows greater suppression of radiation-induced DNA single-strand breaks under hypoxic than aerobic conditions. PR-104 (100 μM; 1 hour; SiHa cells) results in phosphorylation of Ser139 of histone H2AX (gH2AX). PR-104 (0.266 mmol/kg; 18 h; SiHa cells) shows activity against hypoxic cells after irradiation.

Chemical Information
Molecular Weight 579.27
Formula C14H20BrN4O12PS
CAS Number 851627-62-8
Solubility (25°C) DMSO 90 mg/mL
Water 30 mg/mL (ultrasonic and warming)
Storage -80°C, protect from light, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Dean C Singleton, et al. Cancer Gene Ther. Bioreductive prodrυg PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit

[2] Simone Fulda. Blood. Biomarker of sensitivity to PR-104 in leukemia

[3] Maria R Abbattista, et al. Cancer Biol Ther. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

[4] Mark J McKeage, et al. BMC Cancer. PR-104 a bioreductive pre-prodrυg combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

[5] Ghassan K Abou-Alfa, et al. Cancer Chemother Pharmacol. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

Related DNA/RNA Synthesis Products

VVD-214 (RO7589831) is a synthetic lethal allosteric inhibitor of WRN helicase. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity.

Alternariol monomethyl ether

Alternariol monomethyl ether is an alternaria mycotoxin and genotoxin, found in common edible crops. It inhibits the activity of various DNA-topoisomerases, increasing the rate of DNA strand breaks.


APE1-IN-1 is a potent and blood-brain barrier (BBB) penetrant apurinic/apyrimidinic (AP) endonuclease 1 (APE1) inhibitor with an IC50 value of 2 μM. APE1-IN-1 can potentiate the cytotoxicity of the alkylating agents Methylmethane sulfonate to cancer cells.


DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor.

Mating Factor α (1-6)

Mating Factor α (1-6) is a mating factor produced by α-mating type cells of Saccharomyces cerevisiae and an acts as an inhibitor of the initiation of DNA synthesis in the cells.

Abmole Inhibitor Catalog

Keywords: PR-104 supplier, DNA/RNA Synthesis, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.